Ferring Pharmaceuticals, Inc.
400 Rella Boulevard
Suffern
New York
10901
United States
Tel: 914-333-8900
Website: http://www.ferringusa.com/
54 articles with Ferring Pharmaceuticals, Inc.
-
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
-
INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
11/13/2018
INVO Bioscience, Inc. and Ferring Pharmaceuticals announced today that the companies have entered into an exclusive U.S. commercialization rights agreement for INVOcell.
-
NOCDURNA® (desmopressin acetate) Sublingual Tablets Now Available by Prescription in US for Treatment of Nocturia Due to Nocturnal Polyuria
11/9/2018
NOCDURNA is the first and only sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer
10/31/2018
Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities, effective December 31, 2018
-
Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health
10/17/2018
Ferring will access Evotec’s integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates
-
Rebiotix Clinical, Microbiome Data From First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
10/1/2018
New data continues to underscore company leadership in microbiome field.
-
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
-
FDA Approves New Indications for ZOMACTON® (somatropin) as Ferring Plans Launch of Needle-Free Delivery System
7/19/2018
Ferring Pharmaceuticals, Inc.. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications:
-
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
-
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area. -
New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment
7/2/2018
Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response
-
NOCDURNA® (desmopressin acetate) Now Approved by U.S. FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
6/21/2018
The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.
-
Male Fertility Survey Reveals 80 Percent of Men Feel Overlooked When Experiencing Infertility Challenges
6/11/2018
Ferring Pharmaceuticals Inc. (US) has announced findings from a survey conducted with RESOLVE: The National Infertility Association to better understand how men feel when struggling with their own or their partner’s infertility.
-
Ferring to Present Clinical Data on Efficacy and Safety of CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep at Digestive Disease Week
6/5/2018
Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present "A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety of a New Ready-to-Drink Low Volume Bowel Preparation Prior to Colonoscopy" (Poster # Tu2010)
-
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
-
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
-
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.
4/5/2018
Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
-
March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London
3/7/2018
-
Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide
3/5/2018
Agreement to Target New Oral Peptide Development Opportunity, Extending Successful Relationship between Enteris and Ferring